A randomized multicenter Phase 2 clinical trial will include advanced non-small cell lung cancer (NSCLC) patients.
Latest Information Update: 23 Sep 2024
At a glance
- Drugs Maa-T-013 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Sep 2024 According to Maat Pharma media release, this trial is expected to start in H1 2025
- 23 Sep 2024 New trial record